Equities Analysts Set Expectations for Tetraphase Pharmaceuticals, Inc.’s Q3 2017 Earnings (NASDAQ:TTPH)
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) – Research analysts at SunTrust Banks increased their Q3 2017 earnings per share (EPS) estimates for Tetraphase Pharmaceuticals in a report released on Thursday. SunTrust Banks analyst E. Nash now forecasts that the biopharmaceutical company will post earnings per share of ($0.61) for the quarter, up from their prior estimate of ($0.77). SunTrust Banks also issued estimates for Tetraphase Pharmaceuticals’ Q4 2017 earnings at ($0.46) EPS, FY2017 earnings at ($2.62) EPS, FY2018 earnings at ($1.61) EPS, FY2019 earnings at ($1.42) EPS, FY2020 earnings at ($0.28) EPS and FY2021 earnings at $1.07 EPS.
Other equities analysts have also issued research reports about the company. BMO Capital Markets reissued a “buy” rating and issued a $12.00 target price on shares of Tetraphase Pharmaceuticals in a research note on Friday, May 5th. Stifel Nicolaus raised Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and increased their target price for the company from $8.00 to $15.00 in a research note on Wednesday, July 26th. HC Wainwright initiated coverage on Tetraphase Pharmaceuticals in a research note on Tuesday, July 11th. They issued a “buy” rating and a $15.00 target price on the stock. Zacks Investment Research raised Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, July 6th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Tetraphase Pharmaceuticals in a research note on Thursday, July 27th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $10.25.
Tetraphase Pharmaceuticals (NASDAQ TTPH) opened at 5.655 on Monday. The company has a 50-day moving average price of $7.40 and a 200-day moving average price of $6.92. Tetraphase Pharmaceuticals has a 52 week low of $3.11 and a 52 week high of $9.93. The stock’s market cap is $288.70 million.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.76) by $0.07. The company had revenue of $1.59 million during the quarter, compared to analysts’ expectations of $1.54 million. Tetraphase Pharmaceuticals had a negative return on equity of 79.79% and a negative net margin of 2,092.20%. The company’s revenue for the quarter was up 28.2% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.47) EPS.
Several large investors have recently added to or reduced their stakes in the company. GSA Capital Partners LLP raised its stake in Tetraphase Pharmaceuticals by 90.2% in the fourth quarter. GSA Capital Partners LLP now owns 33,600 shares of the biopharmaceutical company’s stock worth $135,000 after buying an additional 15,931 shares in the last quarter. Wade G W & Inc. acquired a new stake in Tetraphase Pharmaceuticals during the first quarter worth approximately $138,000. Teza Capital Management LLC raised its stake in Tetraphase Pharmaceuticals by 8.9% in the first quarter. Teza Capital Management LLC now owns 15,650 shares of the biopharmaceutical company’s stock worth $144,000 after buying an additional 1,281 shares in the last quarter. Citadel Advisors LLC raised its stake in Tetraphase Pharmaceuticals by 18.6% in the first quarter. Citadel Advisors LLC now owns 15,924 shares of the biopharmaceutical company’s stock worth $146,000 after buying an additional 2,496 shares in the last quarter. Finally, Russell Investments Group Ltd. acquired a new stake in Tetraphase Pharmaceuticals during the fourth quarter worth approximately $156,000. 45.48% of the stock is currently owned by institutional investors.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.